BioNTech SE (BNTX)

NASDAQ
Currency in USD
104.40
-0.57(-0.54%)
Closed·
Pre Market
104.70+0.30(+0.29%)
·
BNTX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BNTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
102.24105.20
52 wk Range
76.53131.49
Key Statistics
Edit
Prev. Close
104.4
Open
104.84
Day's Range
102.24-105.2
52 wk Range
76.53-131.49
Volume
895.04K
Average Volume (3m)
1.23M
1-Year Change
21.02%
Book Value / Share
85.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BNTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
134.10
Upside
+28.45%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

BioNTech SE News & Analysis

Show more

BioNTech SE Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE SWOT Analysis


Oncology Ambitions
BioNTech aims for 10 new approvals by 2030, with promising results in lung and breast cancer trials showcasing its ambitious oncology pipeline
Financial Fortitude
$18 billion cash reserves and positive cash flow provide BioNTech with stability and flexibility for R&D investments and strategic acquisitions
Vaccine Legacy
COVID-19 vaccine business continues to generate substantial revenue, funding BioNTech's transition into a diversified biotechnology powerhouse
Market Outlook
Analysts set price targets ranging from $125 to $130, reflecting cautious optimism about BioNTech's oncology potential and financial health
Read full SWOT analysis

BioNTech SE Earnings Call Summary for Q4/2024

  • BioNTech's Q4 EPS of $1.08 and revenue of $1.19B beat forecasts, yet stock fell 2.88% pre-market
  • 2024 net loss of €665M, down from €930M profit in 2023; total revenue fell to €2.8B from €3.8B
  • 2025 revenue projected at €1.7-2.2B; R&D expenses expected to be €2.6-2.8B
  • Focus on oncology expansion, with multiple clinical data updates and potential regulatory submissions planned
  • Strong cash position of €17.4B, but high R&D costs and negative EPS forecasts raise profitability concerns
Last Updated: 2025/03/10, 15:38
Read Full Transcript

Compare BNTX to Peers and Sector

Metrics to compare
BNTX
Peers
Sector
Relationship
P/E Ratio
−29.3x−1.1x−0.5x
PEG Ratio
0.040.010.00
Price/Book
1.2x0.9x2.6x
Price / LTM Sales
8.2x3.7x3.0x
Upside (Analyst Target)
30.1%133.9%51.9%
Fair Value Upside
Unlock18.9%8.9%Unlock

Analyst Ratings

16 Buy
5 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 134.10
(+28.45% Upside)

Earnings

Latest Release
May 05, 2025
EPS / Forecast
-1.73 / -2.00
Revenue / Forecast
182.80M / 204.08M
EPS Revisions
Last 90 days

BNTX Income Statement

FAQ

What Is the BioNTech (BNTX) Stock Price Today?

The BioNTech stock price today is 104.40

What Stock Exchange Does BioNTech Trade On?

BioNTech is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for BioNTech?

The stock symbol for BioNTech is "BNTX."

What Is the BioNTech Market Cap?

As of today, BioNTech market cap is 25.71B.

What Is BioNTech's Earnings Per Share (TTM)?

The BioNTech EPS (TTM) is -3.19.

When Is the Next BioNTech Earnings Date?

BioNTech will release its next earnings report on 03 Aug 2025.

From a Technical Analysis Perspective, Is BNTX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has BioNTech Stock Split?

BioNTech has split 0 times.

How Many Employees Does BioNTech Have?

BioNTech has 6772 employees.

What is the current trading status of BioNTech (BNTX)?

As of 20 Jun 2025, BioNTech (BNTX) is trading at a price of 104.40, with a previous close of 104.40. The stock has fluctuated within a day range of 102.24 to 105.20, while its 52-week range spans from 76.53 to 131.49.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.